The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Trial of Lixisenatide in Early Parkinson’s Disease
Abstract
BACKGROUND: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease. METHODS: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent. RESULTS: A total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%. CONCLUSIONS: In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Three clinical trials consistently describe a slowed decline in motor function when using the short-acting GLP-1 receptor agonists exenatide and lixisenatide in people with Parkinson's disease; 102-104”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [104]
In the citing paper
“The results showed that liraglutide had a modest positive effect on improving motor function and performed well in terms of safety and tolerability, although there were some manageable gastrointestinal side effects.432”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [432]
In the citing paper
“Treatment with exenatide or lixisenatide for 1 year produced a modest but positive effect on Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores in people with recently diagnosed Parkinson’s disease (15, 53).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [53]
In the citing paper
“In Parkinson's disease, phase II trials have shown that GLP-1 RAs such as exenatide and lixisenatide improve motor activity compared to placebo,53,54 and liraglutide has shown improvements in non-motor symptoms, mobility, and quality of life.55”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [54]
In the citing paper
“In addition, lixisenatide slowed motor decline in a phase 2 randomized clinical trial in patients with early Parkinson disease.33”
From Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity (2025) · cites this paper as [33]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Self-citationSystematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
JENKINSON, C., FITZPATRICK, R., PETO, V., GREENHALL, R., & HYMAN, N. (1997) · Age and Ageing · doi:10.1093/ageing/26.5.353 · Cited by 1,321
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G.-L., Widner, H., Mari�, R.-M., R�my, P., Levivier, M., & Conference Participants: Conference Participants: G. L. Defer, M. (. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4<572::aid-mds1005>3.0.co;2-c · Cited by 865
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Self-citationTrial of Prasinezumab in Early-Stage Parkinson’s Disease
Pagano, G., Taylor, K. I., Anzures-Cabrera, J., Marchesi, M., Simuni, T., Marek, K., Postuma, R. B., Pavese, N., Stocchi, F., Azulay, J.-P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202867 · Cited by 421
Cited by
Items 101–200 of 368
Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson’s Disease
Jeong, S. H., & Lee, P. H. (2025) · Journal of Movement Disorders · doi:10.14802/jmd.25008 · Cited by 13
“28 Compared with those receiving placebo, participants receiving lixisenatide exhibited decreased disability, as measured by the MDS-UPDRS part III, with these improvements observed in both the on-and off-medication states.”
Gamborg, M., Grand, M. K., Arvedsen, J., Meaidi, A., & Mørch, L. S. (2025) · European Journal of Neurology · doi:10.1111/ene.70075 · Cited by 13
“disease, reported that lixisenatide (GLP-1RA) prevented worsening of symptoms over a 1-year period based on the Movement Disorder Society–Unified Parkinson's Disease Rating Scale part III compared with placebo [5].”
Au, H. C. T., Lam, P. H., Lim, P. K., & McIntyre, R. S. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106159 · Cited by 20
Lu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 20
Sohail, M. U., Batool, R. M., Aamir, J., Saad, M., Aisha, E., Jain, H., Arshad, M. S., & Ahmed, R. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112239 · Cited by 14
Update on the Present and Future Pharmacologic Treatment of Parkinson’s Disease
Müller, T. H. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00800-3 · Cited by 17
“A similar development occurred in the case of the glucagon-like peptide 1 (GLP-1) receptor agonist lixisenatide [35].”
Udawatta, M., Fidalgo, N., & Mateen, F. J. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07701-7 · Cited by 15
Feng, P., Liu, Z., Lv, D., Hao, W., Li, D., Xue, G., Bai, B., & Hölscher, C. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177972 · Cited by 11
Zhang, Y., Wang, C., Wang, Y., & Wang, T. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13301-y · Cited by 12
Glycation of alpha-synuclein enhances aggregation and neuroinflammatory responses
Vasili, E., König, A., Al‐Azzani, M., Bosbach, C., Gatzemeier, L. M., Thom, S., Chegão, A., Miranda, H. V., Steinem, C., Erskine, D., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01159-w · Cited by 14
“This is particularly relevant given the interest in testing glucagon-like peptide-1 (GLP-1) receptor agonists, such as lixisenatide, in people with early PD 87 .”
Luo, Y., Xia, Y., Gong, X., Hao, M., Wei, Q., & Liao, L. (2026) · BMC Ophthalmology · doi:10.1186/s12886-025-04559-x · Cited by 18
Menon, T., Lee, S. M. L., Gong, X. Y., Wong, S., Le, G. H., Kwan, A. T. H., Teopiz, K. M., Ho, R., Cao, B., Rhee, T. G., et al. (2024) · CNS Spectrums · doi:10.1017/s1092852924000531 · Cited by 17
“In addition, preliminary findings suggest that GLP-1RAs may prevent and treat aspects of psychopathology, including cognitive impairment and mood-related symptoms 25,26,27 .”
Negative findings from trials with NLY01 or deferiprone for Parkinson's disease
Müller, T. H., & Möhr, J.-D. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00097-8 · Cited by 12
Turcano, P., Savica, R., & Benarroch, E. E. (2024) · Neurology · doi:10.1212/wnl.0000000000209781 · Cited by 15
Tumas, V., Aureliano, M. J., Rieder, C. R. D. M., Schuh, A. F. S., Ferraz, H. B., Borges, V., Soares, M. C., Boone, D. L., da Silva, C. C., Costa, M. C., et al. (2025) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0045-1805075 · Cited by 14
Lüth, T., Caliebe, A., Gabbert, C., Sendel, S., Laabs, B., König, I. R., Klein, C., & Trinh, J. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01010-2 · Cited by 13
Avilés-Olmos, I., Espinoza‐Vinces, C., Portugal, L. R., & Luquin, M. R. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01606-1 · Cited by 13
“In a single-blind trial, 12-month exenatide treatment improved motor and cognitive scores compared to controls (MDS-UPDRS difference: +4.9 points; p = 0.037) [ 54, 55].”
InfluentialArnaldi, D., Iranzo, Á., Nobili, F. M., Postuma, R. B., & Videnović, A. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107042 · Cited by 9
Fenaroli, F., Valerio, A., & Ingrassia, R. (2024) · Biomolecules · doi:10.3390/biom14070856 · Cited by 9
“…[34], and its efficacy was recently confirmed in the treatment of motor disability described in a large cohort of patients with early Parkinson’s disease, in a phase 2, double-blind, randomized, placebo-controlled trial (https://clinicaltrials.gov/ ID NCT03439943 (accessed on 13 June 2018) [35]).”
BackgroundWhy do obesity drugs seem to treat so many other ailments?
Lenharo, M. (2024) · Nature · doi:10.1038/d41586-024-03074-1 · Cited by 11
Atomoxetine suppresses radioresistance in glioblastoma via circATIC/miR-520d-5p/Notch2-Hey1 axis
Seok, H. J., Choi, J. Y., Lee, D. H., Shin, I., & Bae, I. H. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01915-0 · Cited by 11
“Therefore, drug discovery through drug repurposing is actively used as an approach to treat many diseases, including cancer treatment [16–19].”
BackgroundAn update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations
Salvadè, M., Luca, M. D., & Gardoni, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117862 · Cited by 14
Nutritional and dietary clinical trials for Parkinson's disease: a narrative review
Giannakis, A., Chondrogiorgi, M., Konitsiotis, S., & Sidiropoulos, C. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02901-7 · Cited by 12
“( Meissner et al. 2024) Furthermore, ongoing research in nutraceuticals drives an increasing interest in their applications in PD management.”
Si, J., Yu, K., Hao, J., Wang, J., & Zhang, L. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251332035 · Cited by 10
“Lixisenatide shows clinical promise for early-stage PD management, 32 while NLY01, a BBB-penetrant novel agonist, ameliorates neurodegeneration and symptoms in murine models of PD and AD.”
Neuroprotection in Parkinson Disease
Gonzalez‐Robles, C., Bandmann, O., & Schapira, A. H. V. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00793-z · Cited by 12
Repurposing metabolic drugs as anti-inflammatory agents
Hogan, A. E., Davis, C., Jenkins, B. J., Jones, N., & O'Shea, D. B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.07.003 · Cited by 14
McIntyre, R. S. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20241087 · Cited by 11
Rai, P., Bathla, G., Praveen, N., Gopikonda, S. S., Chen, H. A., Salim, H. A., Azzam, A. Y., Essibayi, M. A., Altschul, D., Dmytriw, A. A., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13470-w · Cited by 10
Glucagon-like peptide-1 medicines in neurological and psychiatric disorders
Fang, S., Cui, F., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102511 · Cited by 11
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 14
Interactions between antidiabetes medications and heart–brain axis
Ong, L. T., & Sia, C. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000896 · Cited by 8
“In a phase 2 trial involving participants with early Parkinson’s disease, lixisenatide treatment led to a slower progression of motor disability compared to placebo over 12 months [90].”
Cognitive disorders in diabetes
Gariani, K., Ryu, D., & Rizzo, M. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1534105 · Cited by 8
“Similarly, GLP-1 receptor agonists (GLP-1RAs), widely used in diabetes management, have shown promising neuroprotective effects in preclinical studies of neurodegenerative diseases (12, 13).”
Shtilbans, A., Esneault, E., Simon, F., Mazzulli, J. R., Quiriconi, D. J., Rom, D., Reintsch, W., Krahn, A. I., & Durcan, T. M. (2025) · Antioxidants · doi:10.3390/antiox14040396 · Cited by 9
“This is especially interesting in light of the recent clinical trial finding another GLP-1 agonist, lixisenatide (a close homolog of exenatide), showed slower progression of motor disability in early PD [45].”
Kowalska, M. K., El‐Mallul, A., Hudecka, W., Lubojańska, J. E., Lubojański, P. J., Orłowska, S. M., & Bednarczyk, Ł. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041886 · Cited by 9
Malatt, C., Maghzi, H., Hogg, E. J., Tan, E. E., Khatiwala, I., & Tagliati, M. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12989-2 · Cited by 7
Ma, H., Chang, Z., Sun, H., Ma, D., Li, Z., Li, H., Zhang, Z., Hölscher, C., & Zhang, Z. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05037-7 · Cited by 7
DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson’s disease
Jeong, S. H., Kim, Y. J., Shin, J. Y., Oh, K. W., Lee, J. W., & Lee, P. H. (2025) · Gut · doi:10.1136/gutjnl-2025-334988 · Cited by 10
Definite benefits of GLP-1 receptor agonists: what is the risk of gastroparesis and lung aspiration?
Camilleri, M. (2024) · Gut · doi:10.1136/gutjnl-2024-333036 · Cited by 8
“…cardiovascular outcomes in obesity with or without diabetes, 10 11 slowing the motor progression of early Parkinson’s disease with lixisenatide, 12 as well as beneficial effects for primary stroke, major adverse cardiovascular events and cardiovascular mortality prevention based on a…”
Emerging Perspectives on Neuroprotection
Hasler, G., & Inta, D. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000540032 · Cited by 7
“…of systemic metabolic factors to brain pathology is suggested by recent data showing a signi fi cant bene fi cial effect on the progression of illness in patients with Parkinson ’ s disease treated with glucagon-like peptide-1 (GLP-1) receptor agonists used for the treatment of diabetes [58].”
Parkinson’s disease and brain insulin signaling: Mechanisms and potential role of GLP-1 mimetics
Foroozanmehr, B., Hemmati, M. A., Yaribeygi, H., Karav, S., Jamialahmadi, T., & Sahebkar, A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149738 · Cited by 6
Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson’s disease
Lee, S. M. L., Yin, L., Xiao, N., Rhee, T. G., Lo, H. K. Y., Wong, S., Fox, S. H., Teopiz, K. M., Lam, B. Y., Zheng, Y. J., et al. (2025) · CNS Spectrums · doi:10.1017/s109285292510031x · Cited by 9
“34 A population-based cohort study utilized medical records to assess the incidence of PD among persons with T2DM prescribed GLP-1RAs with an overarching aim to determine whether GLP-1RAs mitigate the incidence of PD. 35,40 The primary outcome was the first recorded diagnosis of PD, comparing patients who were prescri…”
InfluentialMouradian, M. M., Stoessl, A. J., & Lang, A. E. (2025) · Movement Disorders · doi:10.1002/mds.30259 · Cited by 8
Badran, A., & Gbreel, M. I. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08411-4 · Cited by 7
Kwan, A. T. H., Lakhani, M., & McIntyre, R. S. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106620 · Cited by 9
Elangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
“…phase 2 and 3 trials support the use of incretin drugs in chronic kidney disease (CKD) [14], osteoarthritis [15], obstructive sleep apnea (OSA) [16] and even in early Parkinson’s disease [17], demonstrating the pleiotropic benefits of these agents in preventing chronic disease progression (Fig.”
Preparing for Parkinson’s disease prevention trials: Current progress and future directions
Bouhadoun, S., Delva, A., Schwarzschild, M. A., & Postuma, R. B. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251334050 · Cited by 9
Yeh, J.-A., Lin, S., Liu, Y., Hsu, J.-Z., Huang, A. H., Munir, K. M., Peng, C. C., Loh, C., & Huang, H. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112914 · Cited by 6
Sobral, M. V. S., Soares, V. G., Moreira, J. L. D. M. L., Rodrigues, L. K., Rocha, P., Bendaham, L. C. A. R., Gonçalves, O. R., Pirolla, R. D. C., Vilela, L. V., de Abreu, V. S., et al. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107210 · Cited by 6
Functional and multi-omic aging rejuvenation with GLP-1R agonismPreprint
Huang, J., Kwok, A. J., Li, J. C. Y., Chiu, C. L. H., Ip, B. Y. M., Tung, L. Y., Zheng, X., Chow, H. T., Lo, M. P. S., Li, Z., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.06.592653 · Cited by 6
Yang, Z., Jiang, X., & Gao, J. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125069 · Cited by 5
Mohammed, O., & Kelemu, T. (2025) · Health Science Reports · doi:10.1002/hsr2.71065 · Cited by 6
“[123].”
Elezz, A. M. A., khalefa, K. A., Gadelmawla, A. F., Khattab, Y. A., & Zeid, M. A. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01873-0 · Cited by 8
Alpha-Synuclein Dysregulation in Systemic Pathophysiology of Synucleinopathies
Dolin, H. H., Zhou, B., & Maitta, R. W. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl27178 · Cited by 5
“Lastly, non-neurologic drugs such as the diabetes drug lixisenatide have been tested in PD patients [69].”
Singh, G., Ansari, S., & Aran, K. R. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01697-5 · Cited by 5
Tsai, W.-W., Lu, K.-H., Wu, J., Chuang, M., Chen, J., Lai, C.-C., Hung, K. C., & Hsieh, M. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251372747 · Cited by 9
“Previous studies have demonstrated their efficacy in neurodegenerative diseases such as Alzheimer’s disease (AD) and PD. 9 GLP-1 RAs enhance mitochondrial function by activating the cyclic adenosine monophosphate/protein kinase A pathway, leading to reduced mitochondrial fragmentation and oxidative stress, and restora…”
InfluentialGlucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Diseases: A Comprehensive Review
Ibrahim, R., Kambal, A., & Abdelmajeed, M. A. (2025) · Cureus · doi:10.7759/cureus.92441 · Cited by 11
Schechter, M., Fishkin, A., Mosenzon, O., Sehtman-Shachar, D. R., Cukierman‐Yaffe, T., Leibowitz, G., & Aharon‐Hananel, G. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02962-8 · Cited by 10
GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review
Orozco, M. P., Rivadeneira, V. V., & León-Rojas, J. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412163 · Cited by 8
“These results suggest lixisenatide might slow clinical decline in early-stage PD [95].”
InfluentialEffects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review
Lee, S., Yin, L., Teopiz, K. M., Wong, S., Le, G. H., Xiao, N., Stahl, S. M., Valentino, K., Ho, R., Zhang, M. C., et al. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251396304 · Cited by 10
“26 Similarly, McGarry et al. 27 and Meissner et al. 28 reported the effects of an investigational GLP-1RA, NLY01, and lixisenatide, respectively, on MDS-UPDRS scores in participants with PD. McGarry et al. 27 enrolled 255 participants with early untreated PD and observed nonsignificant changes in MDS-UPDRS scores betw…”
InfluentialKimura, Y., Koda, T., Kurakami, H., Sakamoto, S., Iwasaki, K., Asai, K., Ge, L., Kato, H., Tsuboi, T., Matsukawa, N., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-112318 · Cited by 12
“To determine the sample size, we refer to the previous clinical trials of exenatide on PD. 11 Required sample size is 66–87 when we set the following parameters: (1) Difference of change in MDS-UPDRS part 3 placebo vs 7 mg is 0–6 and placebo vs 14 mg is 6, (2) Analysis: regression analysis of covariance (ANCOVA) appro…”
InfluentialWu, X., Zhang, L., Luo, S., Li, Q., Wang, J., Chen, W., Zhou, N., Zhou, L., Li, R., Xie, Y., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031301 · Cited by 5
“The disease-modifying activities of lixisenatide (a GLP-1 receptor agonist) demonstrated in clinical trials validate the clinical feasibility of targeting specific pathways [124].”
Microglia heterogeneity and therapeutic strategies in Parkinson’s disease
Tian, J., Liu, X., Wang, Z., Shi, X., Dai, C., & Yang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1739341 · Cited by 6
Late-life semaglutide treatment slows ageing and extends lifespan in female mice
Feng, Y., Barthez, M., Wang, Y., Chen, Y., Qiu, H., Wang, C.-L., Heydari, K., Delcroix, M., Rasmussen, L. J., Bohr, V. A., et al. (2026) · Nature · doi:10.1038/s41586-026-10940-7 · Cited by 7
“2), considering the emerging evidence that GLP-1 medicines have beneficial effects on neurodegeneration 5,50 .”
InfluentialCardiovascular outcomes in Parkinson’s disease patients from a retrospective cohort study
Lim, S., Yum, Y., Kim, J.-H., Lee, C., Joo, H. J., & Kwon, D.-Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-72549-y · Cited by 6
“…Advancement of traditionally cardiovascular medicine such as glucagon-like peptide-1 (GLP-1) analogues in treatment of PD, for example, suggests that cardiovascular diseases and PD may share similar pathophysiologic aspects, enhancing the need to address CV risk factors in patients with PD 32,33 .”
BackgroundAshraf, T., Abunada, O., Kumar, A., Ahmed, S., Siddiqui, M. B. A., Memon, U. F., Dev, S., Meghjiani, A., Turesh, M., Khatri, G., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002908 · Cited by 6
Almeida, O. P. (2025) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000001001 · Cited by 7
To the Brain and Beyond: Neurological Implications of Glucagon-Like Peptide-1 Receptor Agonists
Guevara, L. R. H., Beam, W. B., & Pasternak, J. J. (2024) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0000000000000985 · Cited by 5
“26 An additional study evaluating the impact of GLP-1 RAs on PD, including a longer follow-up period (2 years) using exenatide, is underway.”
Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer’s Disease
Crook, H., & Edison, P. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240730 · Cited by 6
Refractory Nausea and Vomiting Due to Central Nervous System Injury: A Focused Review
Stoica, S., Hogge, C. J., & Theeler, B. J. (2025) · Life · doi:10.3390/life15071021 · Cited by 6
“GLP-1R is expressed on both the GABA-ergic and glutamatergic neuron populations in the AP, which together regulate the induction of satiety and sensation of visceral illness [15,22,34,38–46].”
A mixed methods feasibility study of a ketogenic diet as treatment for Parkinson’s disease
Worster, K., Colgan, D. D., Vita, A. A., McClure, C., Buttolph, L., Hodges, R., Senders, A., Erlandsen, A., Elbarbry, F., & Zwickey, H. L. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1601446 · Cited by 4
“Clinical and in vivo PD studies using repurposed anti-diabetic medications report mixed results but suggest an overall potential modest benefit (50) in motor and cognitive symptoms with GLP-1 receptor agonists taken for at least 12 months (51).”
Shirani, A., & Stüve, O. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2587277 · Cited by 7
“Dosages in these trials have generally mirrored those used in diabetes, such as exenatide 2 mg weekly and lixisenatide 10–20 μg daily [32,46].”
Influentialde Souza, P. C., Bezerra, T. P. W., Rêgo, M. J. B. D. M., & da Rosa, M. M. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.11.025 · Cited by 8
Fang, J., Wang, X., Su, X., Li, D., Wang, F., Wang, P., Yuan, C., Ji, F., Zhang, D., Cai, X., et al. (2025) · The Innovation Life · doi:10.59717/j.xinn-life.2025.100164 · Cited by 7
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 7
Novel drug treatments for schizophrenia
Coyle, J. T., & Paul, S. M. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01335-w · Cited by 10
Stefanou, M., Panagiotopoulos, E., Tentolouris, A., Theodorou, A., Papagiannopoulou, G., Athanasaki, A., Tsalouchidou, P., Peppa, Μ., Lambadiari, V., Konitsiotis, S., et al. (2026) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251408269 · Cited by 8
Choudhury, I., Ward, J. H., Mahesh, S., Alam, U., Azmi, S., & Anson, M. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.02.010 · Cited by 5
Hölscher, C. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261458402 · Cited by 6
“Drugs that can enter the brain readily showed good effects in phase 2 clinical trials, 20,21 while a GLP-1 receptor agonist that does not enter the brain well did not show effects in a phase 2 trial.”
Yang, Y., Chen, L., Zhang, Y., Fu, W., Liu, D., & Jiang, T. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1607443 · Cited by 7
“…Lixisenatide exhibits neuroprotective properties in a mouse model of Parkinson ’ s disease, and early Parkinson ’ s patients receiving Lixisenatide treatment for 12 months experienced a signi fi cant slowing of motor symptoms progression compared to those on placebo (Meissner et al., 2024) Table 1.”
White, A. C., Krout, I. N., Mouhi, S., Blackmer‐Raynolds, L., Chang, J., Kelly, S. D., Caudle, W. M., & Sampson, T. R. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf076 · Cited by 4
Matias, K. V., Gonçalves, V., Scorza, F. A., Finsterer, J., Ciconelli, R. M., & Scorza, C. A. (2025) · Molecules · doi:10.3390/molecules30081672 · Cited by 6
“Conversely, research indicates that there is an increased risk of PD in individuals with type 2 diabetes, and the potential benefit of antidiabetic medication in influencing the course of PD has been suggested [173–177].”
Stinson, S. E., Shadrin, A. A., Rahman, Z., Rødevand, L. N., Broce, I., Persson, K., Selbæk, G., Stefánsson, H., Haavik, J., Parker, N., et al. (2025) · medRxiv · doi:10.1101/2025.07.31.25332114 · Cited by 4
“Notably, clinical trials of GLP-1 receptor agonists (GLP1-RAs), which induce glucose-stimulated insulin secretion, but also prompt significant weight loss, seem to exert neuroprotective effects in AD, with some evidence in PD 28,29 .”
Thiara, D. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0237 · Cited by 3
Nogueira, L., Mazetto, R. A. S. V., Defante, M. L. R., Antunes, V., Gonçalves, O. R., Corso, A. M. S., Coletta, M. V. D., Boone, D. L., Filho, W. S. M., Borges, V., et al. (2025) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0045-1806824 · Cited by 5
Koros, C., Fiske, B. K., & Stefanis, L. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251354935 · Cited by 3
Costa, G. V. L., Cavalcante, L. F. F., Battistuta, S. M., Makabe, P. F., Bueno, I. S. F., Yuamoto, B., Vilela, F., Meloni, L. G. G., de Faria, D. D., Anghinah, R., et al. (2025) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200548 · Cited by 3
Engström, A., Svanström, H., Hviid, A. P., Eliasson, B., Guðbjörnsdóttir, S., Wintzell, V., Hveem, K., Jonasson, C., Melbye, M., Ueda, P., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70760 · Cited by 7
Recent Developments in the Drug Treatment of Parkinson’s Disease
Leiter, S., Mahlknecht, P., & Poewe, W. H. (2026) · Drugs · doi:10.1007/s40265-026-02327-9 · Cited by 4
“Nausea and vomiting were the I n j ec ti on s it e r eac ti on s a nd G I s y m p t o m s c o m - m on most common AEs affecting 46% and 13% of lixisenatide treated patients, respectively and 8% had weight loss [184].”
Siervo, M., Johnston, F., Calton, E. K., James, A. P., Stephan, B. C. M., Hornsby, A. K. E., Davies, J. S., & Burn, D. J. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.10.167 · Cited by 3
The role of amphipathic and cationic helical peptides in Parkinson's disease
Pintado‐Grima, C., & Ventura, S. (2024) · Protein Science · doi:10.1002/pro.70020 · Cited by 3
Cui, H., Li, Z., Sun, H., Zhao, W., Ma, H., Li, H., Zhang, Z., Hölscher, C., Ma, D., & Zhang, Z. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0142 · Cited by 5
Doggrell, S. A. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2459409 · Cited by 3
Lixisenatide in early parkinson’s disease: efficacy, safety, and future directions: a correspondence
Irfan, H., Muneer, S. U., Maheshwari, A. B., Kumar, N., & Iftikhar, S. (2024) · Neurosurgical Review · doi:10.1007/s10143-024-02475-0 · Cited by 3
Kimura, Y., & Mochizuki, H. (2024) · Movement Disorders · doi:10.1002/mds.29884 · Cited by 3
Neuroprotective Activity of GLP-1 Analogues: General Understanding of Implementation Mechanisms
Golovina, E. L., Ваизова, О. Е., & Samojlova, J. G. (2024) · Personalized Psychiatry and Neurology · doi:10.52667/2712-9179-2024-4-2-11 · Cited by 4
Woo, K. A., Jang, Y., Kim, H.-J., & Park, P. J. (2026) · Brain · doi:10.1093/brain/awag130 · Cited by 3
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2024) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2024.09.003 · Cited by 3
Stefano, G. B., Büttiker, P., Weissenberger, S., Raboch, J., & Anders, M. (2025) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2025.101217 · Cited by 4
Invernizzi, F., Ciocca, L., Contaldi, E., Inverso, D., Calandrella, D., Mignone, F., Barichella, M., Isaias, I. U., & Pezzoli, G. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1665957 · Cited by 6
Metadata
- Authors
- Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., Carrière, N., Catala, H., Charif, M., Colin, O., Corvol, J.-C., Damier, P., Dellapina, E., Devos, D., Drapier, S., Fabbri, M., Ferrier, V., Foubert-Samier, A., Frismand-Kryloff, S., Geny, C., Georget, A., Germain, C., Grimaldi, S., Hardy, C., Hopes, L., Krystkowiak, P., Laurens, B., Lefaucheur, R., Mariani, L.-L., Marques, A., Marse, C., Ory-Magne, F., Rigalleau, V., Salhi, H., Saubion, A., Stott, S. R. W., Thalamas, C., Thiriez, C., Tir, M., Wyse, R. K., Benard, A., & Rascol, O.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- French Clinical Research Network for Parkinson’s Disease and Movement Disorders (NS-Park/F-CRIN), France
- Université Côte d'Azur (FR)
- Inserm (FR)
- Clinical Investigation Center CIC1436 and Departments of Clinical Pharmacology and Neurosciences, Centre Expert Parkinson, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse, France
- Université de Bordeaux (FR)
- French Clinical Research Infrastructure Network (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Cure Parkinson’s, London, UK
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Service d’Information Médicale, Clinical Epidemiology Unit (USMR), CHU Bordeaux, F-33000 Bordeaux, France
- ORCID
- Meissner, Wassilios G.
- Maltête, David
- Derkinderen, Pascal
- Houéto, Jean-Luc
- Anheim, Mathieu
- Boraud, Thomas
- Carrière, Nicolas
- Colin, Olivier
- Corvol, Jean-Christophe
- Damier, Philippe
- Dellapina, Estelle
- Devos, David
- Drapier, Sophie
- Fabbri, Margherita
- Grimaldi, Stéphane
- Hopes, Lucie
- Laurens, Brice
- Lefaucheur, Romain
- Mariani, Louise-Laure
- Rigalleau, Vincent
- Stott, Simon R. W.
- Thalamas, Claire
- Thiriez, Claire
- Tir, Mélissa
- Wyse, Richard K.
- Rascol, Olivier
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-04-04
- Volume
- 390
- Issue
- 13
- Pages
- 1176-1185
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4393852482
- Cited by
- 369
- References
- 30
- Citations by year
- 2026: 125 · 2025: 160 · 2024: 83
- FWCI
- 97.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
- Funders
- Cure Parkinson’s
- French Ministry of Health - PHRC-N
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- lixisenatide, Parkinson's disease, GLP-1 receptor agonists, early-stage Parkinson's disease, MDS-UPDRS III, levodopa equivalent daily dose, nausea, neuroprotection, off-medication state, washout period, subcutaneous administration, anti-inflammatory therapy, neurodegeneration, neuroinflammation
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Motor Disorders, Glucagon-Like Peptide-1 Receptor Agonists, Antiparkinson Agents, Double-Blind Method, Persons with Disabilities, Humans, Injections, Subcutaneous, Parkinson Disease, Peptides, Treatment Outcome, Disease Progression, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.